Overview

CMA-676 in Treating Patients With Acute Myeloid Leukemia in First Relapse

Status:
Completed
Trial end date:
2002-02-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of CMA-676 in treating patients with acute myeloid leukemia in first relapse.
Phase:
Phase 2
Details
Lead Sponsor:
Pfizer
Treatments:
Gemtuzumab